Frontlight ResearchEarly access
TerminatedPhase 1/2
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV
Key facts
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 100 people enrolled
- Started
- 1 Jun 2026
- Ended
- 31 Jul 2026
- Type of study
- Interventional
- Treatments tested
- HPV-CTLs
- Record updated
- 3 November 2026
Who can take part
- Age
- 6 months to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Written, informed consent obtained prior to any study-specific procedures
- Evidence of HPV virus activation (viral DNA) or high risk of HPV infection
- Not suitable for routine treatment or invalid to antiviral drugs
- Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA
- Age less than 75 years
- Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics
- Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm\^3, platelet (PLT) ≥ 1,000/mm\^3
- Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2*ULN, Bilirubin ≤ 2*ULN, SGOT/ SGPT ≤ 3*ULN
- If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following criteria:; did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics; white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl
- Human immunodeficiency virus (HIV) test was negative
Who cannot take part
- Subject participated in other investigational somatic cell therapies within past 30 days
- Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive
- Subject is albumin-intolerant
- Subject with life expectancy less than 8 weeks
- Subject with positive pregnancy test result
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.
The group in the trial
- HPV-CTLsTreatment being tested
Autologous or allogenic HPV specific cytotoxic lymphocytes
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection
- Record updated
- 3 November 2026